Skip to main content

Table 1 Baseline characteristics of the study sample

From: Delayed linkage to HIV care among asylum seekers in Quebec, Canada

 Overall (n = 139)First diagnosed in Canada (n = 60)First diagnosed before arrival to Canada (n = 79)
Age (median [IQR])38 [33; 45]37 [33; 44]39 [33; 47]
Sex
 Female88 (63%)31 (52%)57 (72%)
 Male51 (37%)29 (48%)22 (28%)
Sexual orientation
 Heterosexual120 (86%)51 (85%)69 (87%)
 LGBTQ19 (14%)9 (15%)10 (13%)
Country of origin
 Africa
  Nigeria33 (24%)12 (20%)21 (27%)
  Other54 (39%)19 (31%)36 (46%)
 Latin America
  Haiti48 (34%)29 (48%)19 (24%)
  Other4 (3%)0 (0%)3 (4%)
History of sexual- or gender-based violence57 (41%)25 (42%)32 (41%)
 Rape35 (25%)16 (26%)19 (24%)
CD4 at presentation in Canada, cells/μl (median, range, [IQR])415,
7–1221,
[275; 656.5]
307,
11–811,
[221; 401]
574,
7–1221,
[382; 756]
 CD4 < 20022 (16%)13 (22%)9 (11%)
 CD4 < 35052 (37%)37 (62%)15 (19%)
Baseline viral load, copies/ml (median, range, [IQR])1970,
< 20 - > 1 million, [< 20; 41,313]
32,349,
< 20 - > 1 million,
[7890; 100,594]
< 20,
< 20 - > 1 million,
[< 20; 181]
OI at presentation1 (1%)1 (2%)0 (0%)
Requiring primary prophylaxis for OI23 (16%)12 (20%)10 (13%)
cART regimens, baseline
 On cART61 (44%)0 (0%)61 (77%)
  3rd agent
   NNRTI35 (57%)0 (0%)35 (57%)
   PI5 (8%)0 (0%)5 (8%)
   II16 (26%)0 (0%)16 (26%)
   Unknown4 (7%)0 (0%)4 (7%)
  Single tablet regimens41 (67%)0 (0%)41 (67%)
cART regimens, end of study period
 On cART133 (96%)58 (97%)75 (95%)
  3rd agent
   NNRTI8 (6%)1 (2%)7 (9%)
   PI2 (2%)0 (0%)2 (3%)
   II123 (92%)57 (98%)66 (88%)
  Single tablet regimens103 (77%)42 (72%)61 (81%)
TST
 Positive47 (34%)16 (27%)31 (39%)
 Negative84 (60%)41 (68%)43 (54%)
 Not done/missing8 (6%)3 (5%)5 (6%)
Co-infection with HBV8 (6%)4 (7%)4 (5%)
Co-infection with HCV1 (0.7%)0 (0%)1 (1%)
  1. ARV antiretroviral, cART combination antiretroviral therapy, HBV hepatitis B virus, HCV hepatitis C virus, II integrase inhibitor, IQR interquartile range, LGBTQ lesbian, gay, bisexual, transgender, and/or queer, NNRTI non-nucleoside reverse transcriptase inhibitor, OI opportunistic infection, PI protease inhibitor, TST tuberculin skin test